A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailabl
A bioadhesive controlled, extended release progressive hydration composition wherein the active ingredient may be protected from water or the surrounding environment, thereby protecting it from metabolism or from other degradation caused by moisture, enzymes, or pH effects, and making it bioavailable only at a controlled rate. The active ingredient may be protected from moisture during the manufacturing process, as necessary or desired, and more importantly may be protected from moisture and the immediate septic environment until well after the patient has applied the composition, and then only at a slow and controlled rate. It is by this process of progressive hydration that the active ingredient remains protected for many hours after administration. It is also by the process of progressive hydration that controlled and sustained release is achieved because only that part of the active ingredient that is the hydrated (aqueous) fraction of the composition is available for absorption (bioavailable).
대표청구항▼
1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition for delivering an active ingredient to a mucosal surface of a mammal, comprising: an effective amount of a dry reservoir of an active ingredient, anda sustained release active ingredient delivery system c
1. A bioadhesive controlled, sustained release progressive hydration pharmaceutical composition for delivering an active ingredient to a mucosal surface of a mammal, comprising: an effective amount of a dry reservoir of an active ingredient, anda sustained release active ingredient delivery system comprising a bioadhesive water insoluble, water-swellable cross-linked polycarboxylic polymer present in the delivery system in a non-salt form, and a bioadhesive water soluble polymer, wherein the polymers are present in amounts which enable the composition to become progressively hydrated to provide extended release of the active ingredient over time;wherein the delivery system includes amounts of the polymers which are effective to allow the composition to adhere when contacting a mucosal surface of a mammal for a time sufficient to provide extended release of the active ingredient to the mucosal surface. 2. The composition of claim 1, wherein the composition is formulated as a tablet for delivery of the active ingredient via the mucosal surface of a buccal, vaginal, nasal, or rectal cavity. 3. The composition of claim 2, wherein the water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil. 4. The composition of claim 3, wherein the composition is in the form of a tablet that is formulated to gelify or swell to avoid asphyxiation. 5. The composition of claim 3, wherein the water soluble polymer is carbomer 974P. 6. The composition of claim 1, wherein the active ingredient comprises one or more of non-steroidal anti-inflammatory drugs (NSAIDS), anti-infectives, anesthetics, immune system modifiers, muscarinic agonists, muscarinic antagonists, anti-neoplastic agents, vitamin K, ondansetron, levocarnitine, anti-fungals, carbamide peroxide, dopamine antagonists, biphosphonates, nicotine, anti-virals, anti-diabetagenics, peptides, insulin, anti-parkinson agents, low molecular weight heparins, or antimicrobials. 7. The composition of claim 1, wherein the active ingredient comprises one or more of follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (HCG), thyroid-stimulating hormone (TSH), tamoxifen, mifepristone, raloxifene, nitroglycerin, isosorbide, erythrityl tetranitrate, pentaerythritol tetranitrate, terbutaline, albuterol, pirbuterol, bitolterol, ritodrine, propranolol, metoprolol, nadolol, atenolol, timolol, esmolol, pindolol, acebutolol, labetalol, morphine, hydromorphone, oxymorphone, codeine, hydrocodone, oxycodone, levorphanol, levallorphan, buprenorphine, fentanyl, nalbuphine, butorphanol, pentazocine, naloxone, nalmefene, diclofenac, etodolac, fenoprofen, lurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxin, oxaprozin, piroxicam, sulindac, tolmetin, lidocaine, cocaine, chloroprocaine, tetracaine, prilocalne, mepivacaine, buipivacaine, levobupivacaine, articaine, ropivacaine, phenol, benzocaine, pramoxine, dyclonine, etidocaine, procaine, proparacaine, dibucaine, pramoxine, misoprostol, imiquimod, bethanecol, oxybutynin, melphalan, fluorouracil, vinca alkaloids, bleomycin, cisplatin, bromocriptine, acyclovir, metformin, octreotide, desmopressin, GNRH, levodopa, or metronidazole. 8. The composition of claim 1, wherein the active ingredient comprises one or more of estradiol, testosterone, progesterone, terbutaline, prostaglandin E2, desmopressin, metronidazole, or ibuprofen. 9. The composition of claim 8, wherein the active ingredient comprises testosterone and is present in an amount of about 0.04 mg to 45 mg per unit dosage of the composition. 10. The composition of claim 1, wherein the delivery system releases the active ingredient for a period of time longer than the immediate release dosage form of the active ingredient. 11. A method for sustained release delivery of an active ingredient to the bloodstream of a mammal through a mucosal surface which comprises administering to a mucosal surface of a mammal in need of receiving the active ingredient a composition that includes an effective amount of a dry reservoir of the active ingredient and a sustained release active ingredient delivery system comprising a bioadhesive water insoluble, water-swellable cross-linked polycarboxylic polymer in a non-salt form, and a bioadhesive water soluble polymer, wherein the delivery system includes amounts of the polymers which are effective to allow the composition to adhere and progressively hydrate when contacting the mucosal surface of a mammal for a time sufficient to provide extended release of the active ingredient to the mucosal surface. 12. The method of claim 11, wherein the administration is via the mucosal surface of a buccal, vaginal, nasal, or rectal cavity of the mammal. 13. The method of claim 12, wherein the water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil. 14. The method of claim 13, wherein the composition is in the form of a tablet is formulated to gelify or swell to avoid asphyxiation. 15. The method of claim 13, wherein the water soluble polymer is carbomer 974P. 16. The method of claim 11, wherein the active ingredient comprises one or more of non-steroidal anti-inflammatory drugs (NSAIDS), anti-infectives, anesthetics, immune system modifiers, muscarinic agonists, muscarinic antagonists, anti-neoplastic agents, vitamin K, ondansetron, levocarnitine, anti-fungals, carbamide peroxide, dopamine antagonists, biphosphonates, nicotine, anti-virals, anti-diabetagenics, peptides, insulin, anti-parkinson agents, low molecular weight heparins, or antimicrobials. 17. The method of claim 11, wherein the active ingredient comprises one or more of follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (HCG), thyroid-stimulating hormone (TSH), tamoxifen, mifepristone, raloxifene, nitroglycerin, isosorbide, erythrityl tetranitrate, pentaerythritol tetranitrate, terbutaline, albuterol, pirbuterol, bitolterol, ritodrine, propranolol, metoprolol, nadolol, atenolol, timolol, esmolol, pindolol, acebutolol, labetalol, morphine, hydromorphone, oxymorphone, codeine, hydrocodone, oxycodone, levorphanol, levallorphan, buprenorphine, fentanyl, nalbuphine, butorphanol, pentazocine, naloxone, nalmefene, diclofenac, etodolac, fenoprofen, lurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxin, oxaprozin, piroxicam, sulindac, tolmetin, lidocaine, cocaine, chloroprocaine, tetracaine, prilocalne, mepivacaine, buipivacaine, levobupivacaine, articaine, ropivacaine, phenol, benzocaine, pramoxine, dyclonine, etidocaine, procaine, proparacaine, dibucaine, pramoxine, misoprostol, imiquimod, bethanecol, oxybutynin, melphalan, fluorouracil, vinca alkaloids, bleomycin, cisplatin, bromocriptine, acyclovir, metformin, octreotide, desmopressin, GNRH, levodopa, or metronidazole. 18. The method of claim 11, wherein the active ingredient comprises one or more of estradiol, testosterone, progesterone, terbutaline, prostaglandin E2, desmopressin, metronidazole, or ibuprofen. 19. The method of claim 18, wherein the active ingredient comprises testosterone and is present in an amount of about 0.04 mg to 45 mg per unit dosage of the composition. 20. The method of claim 11, wherein the delivery system releases the active ingredient for a period of time longer than the immediate release dosage form of the active ingredient. 21. A method of treating a health condition in a human which comprises administering a tablet to a mucosal surface of the human, wherein the tablet progressively hydrates to release an active ingredient over an extended period of time, the tablet comprising an effective amount of a dry reservoir of the active ingredient, and a sustained release active ingredient delivery system comprising a bioadhesive water insoluble, water-swellable cross-linked polycarboxylic polymer present in a non-salt form, and a bioadhesive water soluble polymer, wherein the delivery system includes amounts of the polymers which are effective to allow the composition to adhere and to progressively hydrate when contacting a mucosal surface of a mammal to provide extended release of the active ingredient to the human. 22. The method of claim 21, wherein the administration is via the mucosal surfaces in a buccal, vaginal, nasal, or rectal cavity of the human. 23. The method of claim 22, wherein the water insoluble, water-swellable cross-linked polycarboxylic polymer is polycarbophil. 24. The method of claim 23, wherein the composition is in the form of a tablet is formulated to gelify or swell to avoid asphyxiation. 25. The method of claim 23, wherein the water soluble polymer is carbomer 974P. 26. The method of claim 21, wherein the active ingredient comprises one or more of non-steroidal anti-inflammatory drugs (NSAIDS), anti-infectives, anesthetics, immune system modifiers, muscarinic agonists, muscarinic antagonists, anti-neoplastic agents, vitamin K, ondansetron, levocarnitine, anti-fungals, carbamide peroxide, dopamine antagonists, biphosphonates, nicotine, anti-virals, anti-diabetagenics, peptides, insulin, anti-parkinson agents, low molecular weight heparins, or antimicrobials. 27. The method of claim 21, wherein the active ingredient comprises one or more of follicle-stimulating hormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin (HCG), thyroid-stimulating hormone (TSH), tamoxifen, mifepristone, raloxifene, nitroglycerin, isosorbide, erythrityl tetranitrate, pentaerythritol tetranitrate, terbutaline, albuterol, pirbuterol, bitolterol, ritodrine, propranolol, metoprolol, nadolol, atenolol, timolol, esmolol, pindolol, acebutolol, labetalol, morphine, hydromorphone, oxymorphone, codeine, hydrocodone, oxycodone, levorphanol, levallorphan, buprenorphine, fentanyl, nalbuphine, butorphanol, pentazocine, naloxone, nalmefene, diclofenac, etodolac, fenoprofen, lurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxin, oxaprozin, piroxicam, sulindac, tolmetin, lidocaine, cocaine, chloroprocaine, tetracaine, prilocalne, mepivacaine, buipivacaine, levobupivacaine, articaine, ropivacaine, phenol, benzocaine, pramoxine, dyclonine, etidocaine, procaine, proparacaine, dibucaine, pramoxine, misoprostol, imiquimod, bethanecol, oxybutynin, melphalan, fluorouracil, vinca alkaloids, bleomycin, cisplatin, bromocriptine, acyclovir, metformin, octreotide, desmopressin, GNRH, levodopa, or metronidazole. 28. The method of claim 21, wherein the active ingredient comprises one or more of estradiol, testosterone, progesterone, terbutaline, prostaglandin E2, desmopressin, metronidazole, or ibuprofen. 29. The method of claim 21, wherein the delivery system releases the active ingredient for a period of time longer than the immediate release dosage form of the active ingredient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (106)
Pitha Josef (Baltimore MD), Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives.
Cuca Robert C. (Edwardsville IL) Lienhop Keith S. (St. Charles MO) Riley ; Jr. Thomas C. (Ballwin MO) Levinson R. Saul (Chesterfield MO) Kirschner Mitchell I. (St. Louis MO), Bioadhesive pharmaceutical delivery system.
Britton Peter (1133 S. Martine Ave. Scotch Plains NJ 07076) Flanagan Patricia (765 S. River Rd. Naperville IL 60540) Hart William P. (47 Wellington Rd. Freehold NJ 07728) Linkin Deborah (315E Medalli, Bioerodible device for administering active ingredients.
Hale Ron L. (Woodside CA) Lu Amy (Los Altos CA) Solas Dennis (San Francisco CA) Selick Harold E. (Belmont CA) Oldenburg Kevin R. (Fremont CA) Zaffaroni Alejandro C. (Atherton CA), Compositions and methods for enhanced drug delivery.
Petit Serge,FRX ; Bourland ; deceased Emile,FRX ITX by Jacqueline Bourland ; legal representative, Compositions for delivery of polypeptides, and methods.
Stanley Theodore H. (Salt Lake City UT) Hague Brian (West Valley City UT), Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments.
Oettel Michael,DEX ; Golbs Siegfried,DEX ; Dittgen Michael,DEX ; Timpe Carsten,DEX ; Graser Thomas,DEX ; Hubler Doris,DEX, Compound preparation for the treatment of hypogonadal men and men with hypophyseal diseases.
Larsson K.ang.re,SEX ; Ljusberg-Wahren Helena,SEX, Controlled release composition forming a reversed micellar (L2) structure or a normal micellar (L1) structure.
El-Rashidy Ragab (Deerfield IL) Ronsen Bruce (River Forest IL) Hassan Emad E. (Sidi Gaber EGX), Controlled release of drugs delivered by sublingual or buccal administration.
Sandow Jurgen (Glashutten/Taunus DEX) Durckheimer Walter (Hattersheim am Main DEX) Ditzinger Gunter (Frankfurt am Main DEX) Merkle Hans-Peter (Zurich CHX), Cyclopeptides and their use as absorption promoters when applied to the mucosa.
Larsson Krister (Malmo SEX) Mellbrand Thomas (Malmo SEX) Mornstam Birgitta (Bunkeflostrand SEX) Roschester Jan (Lund SEX) Skoldback Jan-Ake (Malmo SEX), High purity desmopressin produced in large single batches.
Ceschel Giancarlo (Milan ITX) Segu\ Antonella M. (Milan ITX) Ronchi Celestino (Milan ITX), Liquid pharmaceutical composition for nasal administration containing a polypeptide as active ingredient.
Dumoulin Yves,CAX ; Carriere Fran.cedilla.ois,CAX ; Ingenito Andre,CAX, Manufacture of cross-linked amylose useful as a excipient for control release of active compounds.
Nagai Tsuneji (Chofu JPX) Machida Yoshiharu (Kawasaki JPX) Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX), Method and preparation for administration to the mucosa of the oral or nasal cavity.
Britton Peter (1133 S. Martine Ave. Scotch Plains NJ 07076) Flanagan Patricia (765 S. River Rd. Naperville IL 60540) Hart William P. (47 Wellington Rd. Freehold NJ 07728) Linkin Deborah (315E Medalli, Method for manufacturing buccal delivery device.
Hostetler Karl Y. (Del Mar CA) Kumar Raj (San Diego CA), Method of converting a drug to an orally available form by covalently bonding a lipid to the drug.
Kensil Charlotte A. (Milford MA) Soltysik Sean (Worcester MA) Marciani Dante J. (Hopkinton MA), Methods for enhancing drug delivery with modified saponins.
Ebert Charles D. (Salt Lake City UT) Patel Dinesh C. (Murray UT) Mazer Norman A. (Salt Lake City UT) Venkateshwaran Srinivasan (Salt Lake City UT), Methods for providing testosterone and optionally estrogen replacement therapy to women.
Poli Stefano (Quinto de\Stampi-Rozzano ITX) Coppi Germano (Quinto de\Stampi-Rozzano ITX) Busetti Cesare (Quinto de\Stampi-Rozzano ITX), Oral, cutaneous and intravaginal pharmaceutical compositions in the form of foam.
Larsson Krister (MalmSEX) Mellbrand Thomas (MalmSEX) Mrnstam Birgitta (MalmSEX) Roschester Jan (Lund SEX) Skldbck Jan-Ake (Malm SEX), Process for manufacture of 1-deamino-8-D-arginine vasopressin.
Aiache Jean-Marc (17 rue Marchal Gallini 63000 Clermond-Ferrand FRX), Process for preparing a bioadhesive pharmaceutical dosage form and pharmaceutical dosage form thus prepared.
Suzuki Yoshiki (Hino JPX) Ikura Hiroshi (Hino JPX) Yamashita Gentaro (Koganei JPX), Slow-releasing medical preparation to be administered by adhering to a wet mucous surface.
Schor Joseph M. (Locust Valley NY) Nigalaye Ashok (Jackson Heights NY) Gaylord Norman G. (New Providence NJ), Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.